Primary squamous cell carcinoma of the esophagus initially presenting as a large retroperitoneal mass: A case diagnosed as cancer of unknown primary site

Yu,Lanfang; Ge,Xiaoxiao; Huang,Sui; Wang,Yanli; Shen,Peng

doi:10.3892/mco.2013.79

Primary squamous cell carcinoma of the esophagus initially presenting as a large retroperitoneal mass: A case diagnosed as cancer of unknown primary site

Authors:
- Lanfang Yu
- Xiaoxiao Ge
- Sui Huang
- Yanli Wang
- Peng Shen
View Affiliations

Affiliations: Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China, Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China
Published online on: February 27, 2013 https://doi.org/10.3892/mco.2013.79
Pages: 503-506

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retroperitoneal squamous cell carcinoma (SCC) of unknown origin is uncommon. It is extremely rare when the primary site detected in the esophagus after 18 months. A 59‑year‑old female patient with waist pain was initially diagnosed as retroperitoneal metastatic SCC of occult origin. Six cycles of chemotherapy with cisplatin, paclitaxel and 5‑fluorouracil were administered and clinical complete response was observed. The primary site was detected in the esophagus after 18 months and the overall survival (OS) was 28 months. To the best of our knowledge, this is the first case of esophageal squamous cell carcinoma (ESCC) initially presenting as a metastatic site with long progression‑free survival (PFS) and OS. In conclusion, the different biological characteristics and complete response to first‑line chemotherapy likely contribute to relatively long PFS and OS.

View Figures

View References

1.	Oien KA: Pathologic evaluation of unknown primary cancer. Semin Oncol. 36:8–37. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Hillen HF: Unknown primary tumours. Postgrad Med J. 76:690–693. 2000. View Article : Google Scholar
3.	Pavlidis N, Briasoulis E, Hainsworth J and Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 39:1990–2005. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Greco FA and Hainsworth JD: Tumors of unknown origin. CA Cancer J Clin. 42:96–115. 1992. View Article : Google Scholar : PubMed/NCBI
5.	Pentheroudakis G, Golfinopoulos V and Pavlidis N: Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 43:2026–2036. 2007. View Article : Google Scholar : PubMed/NCBI
6.	van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW and Hillen HF: Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur J Cancer. 38:409–413. 2002.PubMed/NCBI
7.	Akiyama H, Tsurumaru M, Udagawa H and Kajiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 220:364–373. 1994. View Article : Google Scholar : PubMed/NCBI
8.	Chen J, Liu S, Pan J, et al: The pattern and prevalence of lymphatic spread in thoracic oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 36:480–486. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Kelsen DP, Winter KA, Gunderson LL, et al: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 25:3719–3725. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Ruhstaller T, Templeton A, Ribi K, et al: Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie. 33:222–228. 2010. View Article : Google Scholar
11.	Cao W, Xu C, Lou G, et al: A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol. 39:582–587. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Shim HJ, Cho SH, Hwang JE, et al: Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol. 33:624–628. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Honda M, Miura A, Izumi Y, et al: Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal SCC. Dis Esophagus. 23:641–645. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Kim JY, Do YR, Park KU, et al: A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol. 66:31–36. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Overman MJ, Kazmi SM, Jhamb J, et al: Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 116:1446–1453. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR and Wolf RM: Metastatic and histologic presentations in unknown primary cancer. Semin Oncol. 4:53–58. 1977.PubMed/NCBI
17.	Keskin S, Muslumanoglu M, Saip P, et al: Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy. Oncology. 81:30–38. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Untch M, Fasching PA, Konecny GE, et al: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 29:3351–3357. 2011. View Article : Google Scholar
19.	Okamura S, Fujiwara H, Shiozaki A, et al: Long-term survivors of esophageal carcinoma with distant lymph node metastasis. Hepatogastroenterology. 58:421–425. 2011.PubMed/NCBI
20.	Yamamoto Y, Ikeda M, Takashima M, et al: A case of a patient with stage IVa esophageal cancer surviving over 4 years by combination chemotherapy with docetaxel, 5-FU and cisplatin, without operation. Gan To Kagaku Ryoho. 38:1321–1324. 2011.(In Japanese).